Skip to content

Study · Randomized controlled trial · n = 46 · 2015

6 results

Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.

Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, Feldman EL, Pop-Busui R

Journal of diabetes and its complications17 Jul 2015Cited by 72 (Europe PMC)

PMID26264399 (opens in a new tab)PMCIDPMC4656068 (opens in a new tab)DOI10.1016/j.jdiacomp.2015.07.013 (opens in a new tab)PepBankPUB-26264399
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In diabetes with neuropathy, confirmed clinical neuropathy prevalence did not differ significantly between exenatide and glargine.

    In plain wordsIn diabetes with nerve damage, clinical neuropathy prevalence did not differ significantly between exenatide and glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeConfirmed clinical neuropathy prevalence
    Study

    n = 46

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices.
    3 context sentences
    Summary · context
    The primary end point was the prevalence of confirmed clinical neuropathy (CCN).
    Summary · context
    Forty-six T2D subjects (age 54±10years, diabetes duration 8±5years, HbA1c 8.2±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n=24).
    Summary · context
    The subjects, with similar HbA1c levels, were followed for 18months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In diabetes with neuropathy, glucose control was similar with exenatide and insulin glargine.

    In plain wordsIn diabetes with nerve damage, exenatide and insulin glargine provided similar blood sugar control.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucose control
    Study

    n = 46

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Glucose control was similar in both groups during the study.
    2 context sentences
    Summary · context
    Forty-six T2D subjects (age 54±10years, diabetes duration 8±5years, HbA1c 8.2±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n=24).
    Summary · context
    The subjects, with similar HbA1c levels, were followed for 18months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In diabetes with neuropathy, nerve fiber density did not differ significantly between exenatide and glargine.

    In plain wordsIn diabetes with nerve damage, skin nerve density did not differ significantly between exenatide and glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeIntra-epidermal nerve fiber density
    Study

    n = 46

    Comparator
    Insulin glargine
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices.
    2 context sentences
    Summary · context
    Forty-six T2D subjects (age 54±10years, diabetes duration 8±5years, HbA1c 8.2±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n=24).
    Summary · context
    The subjects, with similar HbA1c levels, were followed for 18months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In diabetes with neuropathy, autonomic neuropathy measures did not differ significantly between exenatide and glargine.

    In plain wordsIn diabetes with nerve damage, autonomic nerve measures did not differ significantly between exenatide and glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCardiovascular autonomic neuropathy
    Study

    n = 46

    Comparator
    Insulin glargine
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices.
    2 context sentences
    Summary · context
    Forty-six T2D subjects (age 54±10years, diabetes duration 8±5years, HbA1c 8.2±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n=24).
    Summary · context
    The subjects, with similar HbA1c levels, were followed for 18months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In diabetes with neuropathy, nerve conduction measures did not differ significantly between exenatide and glargine.

    In plain wordsIn diabetes with nerve damage, nerve conduction did not differ significantly between exenatide and glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeNerve conduction
    Study

    n = 46

    Comparator
    Insulin glargine
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices.
    2 context sentences
    Summary · context
    Forty-six T2D subjects (age 54±10years, diabetes duration 8±5years, HbA1c 8.2±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n=24).
    Summary · context
    The subjects, with similar HbA1c levels, were followed for 18months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In diabetes with neuropathy, quality of life indices did not differ significantly between exenatide and glargine.

    In plain wordsIn diabetes with nerve damage, quality of life did not differ significantly between exenatide and glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeQuality of life
    Study

    n = 46

    Comparator
    Insulin glargine
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices.
    2 context sentences
    Summary · context
    Forty-six T2D subjects (age 54±10years, diabetes duration 8±5years, HbA1c 8.2±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n=24).
    Summary · context
    The subjects, with similar HbA1c levels, were followed for 18months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT00855439

Evaluation of Exenatide in Patients With Diabetic Neuropathy

University of Michigann = 46Jun 2008 to May 2014

Type 2 Diabetes Mellitus · Diabetic Peripheral Neuropathy

Trial pageClinicalTrials.govUpdated 1 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.